{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:00:36Z","timestamp":1781154036231,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Given the increasing prevalence of multidrug-resistant opportunistic pathogens and the high mortality rate associated with delayed diagnosis of disseminated infections, there is an urgent need for rapid diagnostic tools and closely monitored, individualized anti-infective strategies. This study aimed to explore the critical role of comprehensive pharmaceutical care in managing disseminated\n                    <jats:italic>Nocardia<\/jats:italic>\n                    infections complicated by complicated urinary tract infection (cUTI). Through detailed documentation of a 67-year-old male patient, this study focuses on optimizing antimicrobial regimens based on pathogenetic findings and adjusting treatments for severe adverse reactions. The patient was diagnosed with disseminated\n                    <jats:italic>Nocardia brasiliensis<\/jats:italic>\n                    infection complicated by\n                    <jats:italic>Enterococcus faecalis<\/jats:italic>\n                    urinary tract infection using metagenomic next-generation sequencing (mNGS). The treatment process underwent two critical adjustments. First, during the efficacy optimization phase, the initial empirical meropenem therapy was modified to a reinforced regimen centered on trimethoprim-sulfamethoxazole (TMP-SMX), combined with linezolid and short-term amikacin, effectively controlling the spread of infection. Subsequently, during the safety optimization phase, the patient developed severe thrombocytopenia during sequential oral therapy. Prompt identification and switching to amoxicillin\/clavulanate potassium resolved the adverse reactions, enabling successful continuation of subsequent treatment. Follow-up revealed a favorable patient recovery. This case demonstrates that for such complex mixed infections, rapid pathogen diagnosis represented by mNGS serves as the starting point for precision treatment, whereas the intensive combination regimen centered on TMP-SMX forms the foundation for controlling disseminated\n                    <jats:italic>Nocardia<\/jats:italic>\n                    infection. More importantly, the core insight from this case is that successful treatment relies not only on appropriate initial medication, but more critically, on proactive, dynamic pharmaceutical monitoring throughout long-term therapy. This enables early intervention for severe adverse drug reactions and timely, flexible adjustments to treatment regimens, which are essential components for ensuring ultimate therapeutic success in patients with such complex infections.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1839868","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:40:22Z","timestamp":1781152822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: pharmaceutical care in a case of complicated urinary tract infection combined with disseminated Nocardia brasiliensis infection"],"prefix":"10.3389","volume":"13","author":[{"given":"Houjun","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital (Dazhou Maternal and Child Health Hospital)","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Pi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital (Dazhou Maternal and Child Health Hospital)","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziru","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhao","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital (Dazhou Maternal and Child Health Hospital)","place":["Dazhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Provincial People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/01.md.0000141100.30871.39","article-title":"Case series and focused review of nocardiosis: clinical and microbiologic aspects.","volume":"83","author":"Lederman","year":"2004","journal-title":"Medicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1128\/CMR.19.2.259-282.2006","article-title":"Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy.","volume":"19","author":"Brown-Elliott","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cmi.2018.06.013","article-title":"Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a french expert laboratory, 2010-2015.","volume":"25","author":"Lebeaux","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"B4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3947\/ic.2023.0032","article-title":"Clinical characteristics, susceptibility profiles, and treatment of nocardiosis: a multicenter retrospective study in 2015-2021.","volume":"130","author":"Kim","year":"2023","journal-title":"Int J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1128\/JCM.06243-11","article-title":"Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey.","volume":"50","author":"Brown-Elliott","year":"2012","journal-title":"J Clin Microbiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1086\/657399","article-title":"Antimicrobial-resistant Nocardia isolates, United States, 1995-2004.","volume":"51","author":"Uhde","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections.","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options.","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e13509","DOI":"10.1111\/ctr.13509","article-title":"Infectious diseases community of practice of the American society of transplantation. Nocardia infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American society of transplantation.","volume":"33","author":"Restrepo","year":"2019","journal-title":"Clin Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0156021","DOI":"10.1128\/spectrum.01560-21","article-title":"Epidemiology and antimicrobial resistance profiles of the Nocardia species in China, 2009 to 2021.","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijantimicag.2016.06.010","article-title":"Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis.","volume":"48","author":"Zhao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"B12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1086\/501356","article-title":"Linezolid-induced inhibition of mitochondrial protein synthesis.","volume":"42","author":"De Vriese","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim\u2013sulfamethoxazole.","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s15010-014-0674-5","article-title":"Risk factors for linezolid-associated thrombocytopenia in adult patients.","volume":"42","author":"Natsumoto","year":"2014","journal-title":"Infection"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1177\/0897190014544786","article-title":"Impact of implementing pharmacist review and monitoring of outpatient parenteral antimicrobial therapy.","volume":"7","author":"Kirkpatrick","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/jac5.1473","article-title":"Role of infectious diseases pharmacists in outpatient intravenous and complex oral antimicrobial therapy: society of infectious diseases pharmacists insights.","volume":"4","author":"Rivera","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1017\/ash.2024.52","article-title":"Bridging the gap: opportunities for transitions of care pharmacist review of outpatient parenteral antimicrobial therapy prescriptions prior to hospital discharge.","volume":"4","author":"Stashluk","year":"2024","journal-title":"Antimicrob Stewardship Healthc Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1017\/ash.2022.374","article-title":"Impact of a pharmacist-managed outpatient parenteral antimicrobial therapy (OPAT) service on cost savings and clinical outcomes at an academic medical center.","volume":"3","author":"Epperson","year":"2023","journal-title":"Antimicrob Stewardship Healthc Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/antibiotics14111103","article-title":"The impact of a structured outpatient parenteral antimicrobial therapy (OPAT) programme on quality of care, optimisation of antimicrobial use, and healthcare costs: a retrospective cohort study.","volume":"14","author":"Manders","year":"2025","journal-title":"Antibiotics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"107306","DOI":"10.1016\/j.ijid.2024.107306","article-title":"Evolution of pharmacist roles in antimicrobial stewardship: a 20-year systematic review.","volume":"151","author":"Nampoothiri","year":"2025","journal-title":"Int J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/antibiotics14050451","article-title":"Delivery of outpatient parenteral antimicrobial therapy (OPAT) in an ever-changing national health service (UK): benefits, barriers, and opportunities.","volume":"14","author":"Durojaiye","year":"2025","journal-title":"Antibiotics"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1839868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:40:45Z","timestamp":1781152845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1839868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1839868"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1839868","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1839868"}}